India, April 14 -- Pharmaceutical company Harmony Biosciences Holdings, Inc. (HRMY) announced Tuesday the appointment of Glenn Reicin as Chief Financial Officer, effective immediately. Harmony is also reiterating its 2026 net product revenue guidance of $1.0 to $1.04 billion.
Reicin is a seasoned biopharmaceutical executive with extensive experience across publicly traded and privately held companies.
As CFO and a member of the Executive Team, Reicin will play a pivotal role in helping to drive the execution of Harmony's key strategic priorities. He will oversee Harmony's finance organization, including financial planning and analysis, accounting, treasury, investor relations, and risk management.
Most recently, Reicin served as Chief Fi...